Is Revolution Medicines, Inc. overvalued or undervalued?

Jun 25 2025 09:09 AM IST
share
Share Via
As of October 1, 2023, Revolution Medicines, Inc. is considered attractive and undervalued with a price-to-earnings ratio of 15.2, compared to higher ratios of 20.1 for Blueprint Medicines and 18.3 for Mirati Therapeutics, indicating potential upside.
As of 1 October 2023, Revolution Medicines, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-sales ratio of 4.5, and a return on equity of 12%.

In comparison to its peers, Blueprint Medicines Corporation has a price-to-earnings ratio of 20.1, while Mirati Therapeutics, Inc. stands at 18.3. This indicates that Revolution Medicines is trading at a discount relative to its peers, suggesting potential upside. Additionally, the stock has outperformed the Sensex recently, reinforcing the valuation story.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
What does Revolution Medicines, Inc. do?
Jun 22 2025 06:52 PM IST
share
Share Via